VERU INC. Amortization of Debt Issuance Costs and Discounts
VERU INC. (VERU) reported Amortization of Debt Issuance Costs and Discounts of $1.46 million for the 12-month period ending 2021-09-30, per its 10-K filed 2022-12-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2022-12-05
- VERU INC. amortization of debt issuance costs and discounts for the quarter ending 2021-09-30 was $59.29K, a 90.78% decline year-over-year.
- VERU INC. amortization of debt issuance costs and discounts for the quarter ending 2021-06-30 was $327.55K, a 58.12% decline year-over-year.
- VERU INC. amortization of debt issuance costs and discounts for the quarter ending 2021-03-31 was $499.63K, a 40.84% decline year-over-year.
- VERU INC. amortization of debt issuance costs and discounts for the quarter ending 2020-12-31 was $572.86K, a 33.54% decline year-over-year.
- VERU INC. amortization of debt issuance costs and discounts for fiscal 2021 was $1.46M, a 53.40% decline from fiscal 2020.
- VERU INC. amortization of debt issuance costs and discounts for fiscal 2020 was $3.13M, a 22.43% decline from fiscal 2019.
- VERU INC. amortization of debt issuance costs and discounts for fiscal 2019 was $4.04M, a 50.27% increase from fiscal 2018.
- VERU INC. amortization of debt issuance costs and discounts for fiscal 2018 was $2.69M.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2021-09-30 | $59.29K derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $386.84K derived: sum of 2 quarters · filed 2022-12-05 | $886.47K derived: sum of 3 quarters · filed 2022-12-05 | $1.46M 10-K · filed 2022-12-05 |
| 2021-06-30 | $327.55K 10-Q · filed 2022-08-11 | $827.18K derived: sum of 2 quarters · filed 2022-08-11 | $1.40M 10-Q · filed 2022-08-11 | $2.04M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $499.63K 10-Q · filed 2022-05-12 | $1.07M 10-Q · filed 2022-05-12 | $1.72M derived: sum of 3 quarters · filed 2022-05-12 | $2.50M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $572.86K 10-Q · filed 2022-02-09 | $1.22M derived: sum of 2 quarters · filed 2022-02-09 | $2.00M derived: sum of 3 quarters · filed 2022-02-09 | $2.84M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-09-30 | $642.90K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $1.43M derived: sum of 2 quarters · filed 2021-12-02 | $2.27M derived: sum of 3 quarters · filed 2021-12-02 | $3.13M 10-K · filed 2021-12-02 |
| 2020-06-30 | $782.17K 10-Q · filed 2021-08-12 | $1.63M derived: sum of 2 quarters · filed 2021-08-12 | $2.49M 10-Q · filed 2021-08-12 | $3.34M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $844.59K 10-Q · filed 2021-05-12 | $1.71M 10-Q · filed 2021-05-12 | $2.56M derived: sum of 3 quarters · filed 2021-05-12 | $3.48M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $861.99K 10-Q · filed 2021-02-10 | $1.71M derived: sum of 2 quarters · filed 2021-02-10 | $2.63M derived: sum of 3 quarters · filed 2021-02-10 | $3.74M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-09-30 | $849.35K derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-10 | $1.77M derived: sum of 2 quarters · filed 2020-12-10 | $2.88M derived: sum of 3 quarters · filed 2020-12-10 | $4.04M 10-K · filed 2020-12-10 |
| 2019-06-30 | $922.14K 10-Q · filed 2020-08-13 | $2.03M derived: sum of 2 quarters · filed 2020-08-13 | $3.19M 10-Q · filed 2020-08-13 | $4.30M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $1.11M 10-Q · filed 2020-05-13 | $2.27M 10-Q · filed 2020-05-13 | $3.38M derived: sum of 3 quarters · filed 2020-05-13 | $4.63M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $1.16M 10-Q · filed 2020-02-12 | $2.27M derived: sum of 2 quarters · filed 2020-02-12 | $3.53M derived: sum of 3 quarters · filed 2020-02-12 | $3.84M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-09-30 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-12 | $2.37M derived: sum of 2 quarters · filed 2019-12-12 | $2.69M derived: sum of 3 quarters · filed 2019-12-12 | $2.69M 10-K · filed 2019-12-12 |
| 2018-06-30 | $1.26M 10-Q · filed 2019-08-08 | $1.57M derived: sum of 2 quarters · filed 2019-08-08 | $1.57M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $317.75K 10-Q · filed 2019-05-15 | $317.75K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |